Orion Portfolio Solutions LLC Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Orion Portfolio Solutions LLC lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 57.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,390 shares of the medical research company's stock after selling 1,847 shares during the quarter. Orion Portfolio Solutions LLC's holdings in Charles River Laboratories International were worth $257,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Charles River Laboratories International by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock valued at $1,136,938,000 after acquiring an additional 60,497 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after purchasing an additional 47,221 shares during the last quarter. Sei Investments Co. grew its holdings in Charles River Laboratories International by 6.1% during the fourth quarter. Sei Investments Co. now owns 673,868 shares of the medical research company's stock valued at $124,394,000 after purchasing an additional 38,827 shares during the period. Charles Schwab Investment Management Inc. increased its position in Charles River Laboratories International by 7.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 552,975 shares of the medical research company's stock worth $102,079,000 after buying an additional 37,753 shares during the last quarter. Finally, Norges Bank purchased a new stake in Charles River Laboratories International in the fourth quarter worth $98,886,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

CRL has been the subject of several research reports. Barclays cut their price target on Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price for the company in a research report on Monday, March 3rd. Robert W. Baird lowered their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. The Goldman Sachs Group cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and dropped their price target for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Finally, Morgan Stanley reduced their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $182.00.

Insider Activity

In other Charles River Laboratories International news, CEO James C. Foster purchased 6,075 shares of the business's stock in a transaction on Thursday, February 20th. The stock was acquired at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares in the company, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Birgit Girshick acquired 1,514 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Price Performance

Shares of CRL traded down $0.38 during trading hours on Tuesday, reaching $106.22. 356,154 shares of the company's stock traded hands, compared to its average volume of 1,455,264. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The stock has a market cap of $5.22 billion, a PE ratio of 706.30, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The firm's 50 day simple moving average is $155.52 and its 200-day simple moving average is $176.21.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. During the same quarter in the previous year, the company earned $2.46 EPS. The business's quarterly revenue was down 1.1% compared to the same quarter last year. Equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).